|
| NB: The information displayed below does not replace the protocol. The latest protocol version should always be consulted before making clinical decisions. |
|
TACT
|
|
A randomised trial of standard anthracycline-based chemotherapy with fluorouracil, epirubicin and cyclophosphamide (FEC) or Epirubicin and CMF (Epi-CMF) vs FEC followed by sequential docetaxel as adjuvant treatment for women with early breast cancer
|
|
|
Topic
|
|
Cancer
|
|
Portfolio Eligibility
|
|
Funded by UKCRC partner
|
|
|
ISRCTN
|
79718493
|
|
EudraCT
|
|
|
MREC N° |
20/05/2001
|
|
UKCRN ID |
770
|
|
WHO ID
|
|
|
|
Research Summary
|
A randomised trial of standard anthracycline-based chemotherapy with fluorouracil, epirubicin and cyclophosphamide (FEC) or epirubicin and CMF (Epi-CMF) versus FEC followed by sequential docetaxel as adjuvant treatment for women with early breast cancer
|
|
|
Study Type |
Interventional
|
|
Design Type |
Treatment
|
|
Disease(s) |
Breast
|
|
Phase |
III
|
|
|
Current Status
| Closed - in follow-up |
| Closure Date | 16/06/2003 |
|
Sample Size
| 3340 |
| Accrual to Date |
 | 124% |
|
|
|
Geographical Scope
| UK Multi-Centre |
|
Lead Country
| Unknown (also active in England and Scotland and Wales) |
|
|
Main Inclusion Criteria
|
Patients with operable histologically confirmed completely resected invasive breast cancer for whom adjuvant chemotherapy is indicated.
No clinical or radiological evidence of locoregional or metastatic disease based on standard staging procedures at local centres.
WHO performance status of 0 or 1.
Chemotherapy to start within < 8 weeks from date of definitive surgery.
Aged > 18 years (no upper age limit).
Hormone receptor status to be determined prior to randomisation.
Adequate renal, hepatic and bone marrow function.
Signed written informed consent.
|
|
|
Main Exclusion Criteria
|
|
not specified
|
|
|
Chief Investigator(s)
|
| Prof Peter Barrett-Lee | Dr Paul Ellis |
|
|
Further details, please contact
|
Ms Jane Banerji
Institute of Cancer Research
Clinical Trials & Statistics Unit (ICR-CTSU)
Section of Clinical Trials
Brookes Lawley Building
15 Cotswold Road
Sutton
SM2 5NG
UNITED KINGDOM
Tel: 0208 722 4299
Jane.Banerji@icr.ac.uk
|
|
|
Funder(s) |
Pharmacia and Upjohn
Cancer Research UK
Sanofi-Aventis
Roche Ltd
|
|
Sponsor(s) |
Institute of Cancer Research
|
|
|
|